Provided by Tiger Trade Technology Pte. Ltd.

Ironwood Pharmaceuticals

4.13
+0.29007.55%
Post-market: 4.11-0.0200-0.48%19:56 EDT
Volume:7.11M
Turnover:29.11M
Market Cap:679.85M
PE:6.91
High:4.17
Open:3.79
Low:3.79
Close:3.84
52wk High:5.78
52wk Low:0.6701
Shares:164.61M
Float Shares:127.00M
Volume Ratio:2.88
T/O Rate:5.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.5973
EPS(LYR):0.1484
ROE:-574.72%
ROA:33.15%
PB:-3.13
PE(LYR):27.83

Loading ...

Ironwood Pharmaceuticals shareholders approve 10 million-share increase to equity incentive plan

Reuters
·
Jun 19

Ironwood Pharma Director Julie McHugh disposes of 21,571 shares worth $80,449.83

Reuters
·
Jun 18

BRIEF-Ironwood Pharmaceuticals Repaid In Full $200 Million 1.5% Convertible Senior Notes Due 2026

Reuters
·
Jun 16

Ironwood Pharmaceuticals - Funded Repayment of Notes Using Available Cash on Hand - SEC Filing

THOMSON REUTERS
·
Jun 16

Ironwood repays $200 million 1.5% convertible notes at maturity

Reuters
·
Jun 16

Ironwood Pharmaceuticals Signals Blockbuster Momentum in 2026

TIPRANKS
·
Jun 02

Ironwood Pharma to join Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 29

FDA Approves Use Of Linzess In Pediatric Patients Aged 2 & Older With Functional Constipation

Reuters
·
May 27

FDA approves Ironwood’s Linzess for functional constipation in children aged 2 and older

Reuters
·
May 27

Ironwood Pharmaceuticals - Linzess Contraindicated in Patients Under 2 Years Due to Risk of Serious Dehydration

THOMSON REUTERS
·
May 27

Ironwood Pharmaceuticals Inc: Linzess Is Contraindicated in Patients With Known or Suspected Mechanical Gastrointestinal Obstruction

THOMSON REUTERS
·
May 27

FDA Approves Use of Linzess® (Linaclotide) in Pediatric Patients Two Years of Age and Older With Functional Constipation (Fc)

THOMSON REUTERS
·
May 27

Ironwood amends 8-K to disclose interim CFO Ronald Silver’s $12,250 monthly fee

Reuters
·
May 22

Kyverna names Greg Martini CFO, succeeding Marc Grasso

Reuters
·
May 18

Ironwood CFO Gregory Martini resigns, Ronald Silver named interim CFO

Reuters
·
May 13

Ironwood Pharmaceuticals Inc - Appoints Ronald Silver as Interim CFO Effective May 15, 2026 - SEC Filing

THOMSON REUTERS
·
May 13

Ironwood Pharmaceuticals Inc - Gregory Martini Resigns as CFO Effective May 15, 2026 - SEC Filing

THOMSON REUTERS
·
May 13

Ironwood Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07

Ironwood Q1 revenue jumps 159%, beats analyst expectations

Reuters
·
May 07

BRIEF-Ironwood Pharmaceuticals Q1 Revenue USD 106.506 Million Vs. IBES Estimate USD 92.1 Million

Reuters
·
May 07